8-KCorporate ChangesExhibits & Filings

AbbVie Inc. 8-K Report, Bylaw Amendment (Feb 22, 2016)

Filed February 22, 2016For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed an 8-K report on February 22, 2016, to announce significant amendments to its corporate bylaws, effective February 18, 2016. The primary focus of these amendments is the adoption of proxy access, a mechanism that allows eligible shareholders to nominate directors for inclusion in the company's proxy materials. This change is notable for investors as it alters the landscape for shareholder engagement and corporate governance. The new bylaw permits a group of up to 20 shareholders, collectively holding at least 3% of the company's outstanding common stock continuously for three years, to nominate director candidates. These nominees can constitute up to 25% of the Board of Directors, commencing with the company's 2017 annual meeting. This move reflects a broader trend of companies adopting proxy access in response to shareholder advocacy and evolving governance standards.

Key Highlights

  • 1AbbVie adopted Amended and Restated By-laws on February 18, 2016.
  • 2The core amendment implements 'proxy access', allowing shareholders to nominate directors.
  • 3Shareholders must collectively own at least 3% of outstanding common stock for a minimum of three continuous years to utilize proxy access.
  • 4A group of up to 20 shareholders can collaborate to nominate directors under the proxy access provision.
  • 5Nominees can represent up to 25% of AbbVie's Board of Directors.
  • 6The proxy access provision will be effective for the company's 2017 annual shareholder meeting.
  • 7Related technical and administrative changes were made to Sections 2.8 and 2.10 of the bylaws.

Frequently Asked Questions

Proxy access is a corporate governance provision that allows eligible shareholders to nominate directors for election to a company's board and have those nominations included in the company's official proxy materials. AbbVie is implementing proxy access to enhance shareholder engagement and align with evolving corporate governance practices, likely in response to shareholder proposals or broader industry trends.

To use proxy access, a shareholder, or a group of up to 20 shareholders, must have continuously owned at least 3% of AbbVie's outstanding common stock for a minimum of three years prior to the nomination.

Eligible shareholders can nominate director candidates that constitute up to 25% of the total number of directors on AbbVie's Board of Directors.

The proxy access provision, as detailed in the Amended and Restated By-laws, will be effective beginning with AbbVie's 2017 annual meeting of shareholders.